French biotech Valneva has the green light to begin human trials for its investigational Lyme disease vaccine. There's a clear need, but the complex market has already rejected an effective vaccine, back in 2002.
Take Two: Valneva Pursues a Successful Lyme Disease Vaccine
Comment
Show comments
Hide Comments
